COPY NUMBER CHANGES IN 1q21.3 AND 1q23.3 HAVE DIFFERENT CLINICAL RELEVANCE IN OVARIAN TUMORS
Dimova I1, Orsetti B2, Theillet Ch.2, Dimitrov R.3, Toncheva DI1,*
*Corresponding Author: Draga I. Toncheva, Department of Medical Genetics, Medical Faculty, Medical University, 2 Zdrave str. SBALAG “Maichin dom,” 6 Fl., 1431, Sofia, Bulgaria; Tel./Fax: +35-92-952-0357; E-mail: dragatoncheva@yahoo.com
page: 29

MATERIALS AND METHODS

Ovarian Tumors for Tissue Microarray (TMA) Construction. A TMA containing 540 ovarian tumor samples from 540 patients was con­structed. The average age of the patients in the co­hort was 55.25 years. There were 278 malignant tu­mors, 39 low malignant potential tumors (LMP) and 223 benign tumors (Table 1). The histological vari­ants were: 248 serous, 61 mucinous, 85 endometri-oid, two clear cell tumors, two Brenner tumors, 20 mixed epithelial tumors, 31 undifferentiated, 21 un­classified and 50 non epithelial tumors (granulosa-cell, germline-cell). The slides from all tumors were previously reviewed by a single pathologist. Tumor stage and grade were defined according to the Inter­national Federation of Gynecology and Obstetrics

(FIGO) and World Health Organization (WHO) cri­teria [11].

Investigated Bacterial Artificial Chromo­some Clones from 1q and Genes They Contain. We investigated the BAC of 1q21.3-RP11-126K1, of 168,686 bp (http://genome.ucsc.edu/). This contains the following genes: PIP5K1A; RFX5; PIK4CB; SELENBP1, which encode for phospha-ditylinositol-4-phosphate-5-kinase a, RFX5 protein (involved in expression of MHC-II), phosphadityl-inositol-3-kinase, and Selen-binding protein 1, re­spectively.

We also investigated the BAC of 1q23.3-RP11-97G24, of 171,855 bp. It contains the genes SLAMF1; SLAMF6; CD84, which encode for sig­naling lymphocytic activation molecule family member 1 (involved in cytolysis activity of NK cells), signaling lymphocytic activation molecule family member 6, and protein of super family of immunoglobulin receptors, respectively.

Tissue Microarray. For TMA construction, a hematoxilin and eosin (H&E)-stained section was made from each block to define representative tumor areas. Tissue cylinders with a diameter of 0.6 mm were punched from tumor areas and brought into a recipient paraffin block using a custom-made pre­cision instrument [12]. Samples were distributed in

one regular-sized recipient paraffin block contain­ing 540 specimens. Five pm sections of the blocks were transferred to glass slides using a paraffin-sec­tioning aid system (adhesive coated slides, adhesive tape, UV-lamp; Instrumedics Inc., Hackensack, NJ, USA).

Fluorescence in situ Hybridization (FISH).

Prior to hybridization the slides were treated with xylene at 37°C, absolute ethanol at room tempara-ture and 1 M sodium thiocyanate at 80° C for depar-rafinization and pretreatment. Dual color FISH was performed using the locus RP11-126K1 (1q21.3) clone probe, conjugated with digoxigenin and de­tected in red, and locus RP11-97G24 (1q23.3) clone probe, conjugated with biotin and detected in green. Labeling of the probes was performed by nick-trans­lation. Denaturation of the DNA was carried out at 75°C for 10 min. (probe mixture) or at 73°C for 5 min. (slides). The probe mixture was applied to the slides and hybridized overnight in a moist cham­ber at 37°C. The post hybridization washes were performed using formamide 50%/2xSSC. A three-step detection was achieved by blocking non spe­cific signals with block buffer, first detection with FITC-avidin/ mouse anti-Dig, again blocking, sec­ond detection with anti-avidin/Dig anti-mouse IgG, blocking, and third detection with FITC-avidin/ anti-Dig rhodamine. The slides were counterstained with DAPI in antifade. The presence of more than five locus signals per cell or tight clusters in at least 10% of tumor cells was considered to connote am­plification. The presence of 3-5 locus signals in at least 10% of tumor cells was considered to connote a gain.

Statistical Analysis. The relationship between copy number changes and clinicopathological data was estimated using the %2 test and the p value was calculated. A p value of <0.05 was required for sig­nificance.




Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006